Chronic venous insufficiency
Conditions
Interventions
Experimental group: 10 patients will use compression stockings containing nanoencapsulated hesperetin and placebo for oral use (every 12 hours)
Control group: 10 patients will use conventional compression stocking and venoactive drug (hesperidin 450 mg + diosmin 50 mg) for oral use (every 12 hours)
Placebo group: 10 patients will use conventional compression stocking and placebo for oral use (every 12 hours). All patients should wear the received stockings immediately after waking up and remain
Drug
Other
H01.603
Sponsors
Universidade Federal de Sergipe
Universidade Federal de Sergipe
Eligibility
Age
30 Years to 59 Years
Inclusion criteria
Inclusion criteria: Volunteers with varicose veins, varicose veins plus edema, hyperpigmentation, lipodermatosclerosis, healed venous ulcer or active ulcer; age between 30 and 59 years; both genders; similar impairment of the saphenous vein
Exclusion criteria
Exclusion criteria: Volunteers with telangiectasias; cognitive alterations; diabetics; neuropaths; with erysipelas; lymphangitis; deep vein thrombosis; ulcer of non-venous origin; psychiatric disorders; demence; without speaking or understanding the Portuguese language; use of antibiotic or venoactive drugs in the last six months prior to the start of the research; sclerotherapy of lower limbs; surgical procedure; use of Unna boot, multi-layer dressing or dressing with topical medicine; children; morbidly obese; pregnant women; infants; patients at risk of pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected Outcome 1: Healing of ulcers in the six-month period comprised in the study, verified by reduction of the size of the wound using the software Image J. The lesions with reduction greater than 70% of their total extension will be considered healed.;Expected Outcome 2: Improvement in patients' quality of life after six months of treatment. This outcome will be measured by the volunteers' responses to the Aberdeen questionnaire and the Wilcoxon test will be performed to check whether the patients achieved (p <0.05) or did not improve satisfactorily. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of pain reported by the volunteer in the EVA questionnaire. This outcome will be measured according to the patients' responses using the Wilcoxon test to check whether the patients achieved (p <0.05) or did not improve satisfactorily. | — |
Countries
Brazil
Contacts
Public ContactPaula Menezes
Universidade Federal de Sergipe
Outcome results
None listed